Wednesday, 28 February 2018

Mylan teams up with Revance on biosimilar for Botox

NEW YORK (Reuters) - Mylan NV on Wednesday struck a licensing agreement to help bring Revance Therapeutics Inc's biosimilar of Allergan Plc's blockbuster Botox wrinkle treatment to the market.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)